ArticleAnnals of translational medicine2019
Incidence and survival outcomes of early male breast cancer: a population-based comparison with early female breast cancer.
Article in Annals of translational medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Influence of tumour grade on disease survival in male breast cancer patients: a systematic review.Breast cancer research and treatment · 2024Pooled it
- Experiences and perceptions of men following breast cancer diagnosis: a mixed method systematic review.BMC cancer · 2024Pooled it
- Locally advanced breast cancer in an elderly male with end-stage renal disease: A case report.Oncology letters · 2026Article
- Case Report: long-term survival of a male patient with breast cancer complicated by lung adenocarcinoma treated with individualized therapy.Frontiers in oncology · 2026Article
- Long-term trends in the incidence of male breast cancer and nomogram for predicting survival in male breast cancer patients: a population-based epidemiologic study.Scientific reports · 2025Article
- Development and Validation of a Prognostic Nomogram Model for HER2-Positive Male Breast Cancer Patients.Asian Pacific journal of cancer prevention : APJCP · 2024Article
- Matched-pair long-term survival analysis of male and female patients with breast cancer: a population-based study.Translational breast cancer research : a journal focusing on translational research in breast cancer · 2024Article
- Moderate Intensity Exercise Reduces Side Effects of Cancer Therapy and Maintains Cardiorespiratory Fitness in Male Breast Cancer Patients: Findings from the BRECA Male Crossover Study.Breast care (Basel, Switzerland) · 2023Article
- Clinicopathological features of male patients with breast cancer based on a nationwide registry database in Japan.Breast cancer (Tokyo, Japan) · 2022Article
- Survival Analysis in Male Breast Cancer With Bone Metastasis Based on the SEER Database.Frontiers in oncology · 2022Article
- Genetic Landscape of Male Breast Cancer.Cancers · 2021Review
- Sex-Based Heterogeneity in the Clinicopathological Characteristics and Prognosis of Breast Cancer: A Population-Based Analysis.Frontiers in oncology · 2021Article
- Identifying Clinicopathological Risk Factors of the Regional Lymph Node Metastasis in Patients with TJournal of oncology · 2021Article
- A DNA Methylation-Based Panel for the Prognosis and Dagnosis of Patients With Breast Cancer and Its Mechanisms.Frontiers in molecular biosciences · 2020Article
- An introduction to male breast cancer for urologists: epidemiology, diagnosis, principles of treatment, and special situations.International braz j urol : official journal of the Brazilian Society of UrologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMale breast cancer (MBC) is a rare malignancy. We aimed to analyze the incidence trends, clinicopathological characteristics, and survival outcomes in early MBC comparison with early female breast cancer (FBC).
methodsWe included eligible MBC and FBC patients with stage I-II disease in the Surveillance, Epidemiology, and End Results (SEER) database from 2000-2015. Joinpoint regression was used to evaluate the trends in age-adjusted incidence. A one-to-four propensity score matching (PSM) analysis was performed to reduce bias in a retrospective study. Survival outcomes were evaluated using Kaplan-Meier analyses with the log-rank test and Cox proportional hazards regression analysis.
resultsTrends in the age-adjusted incidence rates of early MBC were stable [2000-2015, annual percentage change (APC) =0.50, 95% confidence interval (CI): -0.1 to 1.1, P=0.102]; however, the incidence of early FBC changed significantly over the time period (2000-2015, APC = 0.30, 95% CI: 0.0 to 0.6, P=0.045). In the matched cohort, unmarried status, higher grade, larger tumor size, and advanced lymph node (LN) status were associated with a higher risk of breast cancer death and death of any causes both in early MBC and FBC patients. The hormone receptor (HR) status was as a prognostic factor in FBC patients, but not in MBC. Early MBC had worse breast cancer-specific survival (BCSS) and overall survival (OS) than early FBC in stage I, stage II and HR-positive subgroup of patients.
conclusionsThe biological behavior, clinicopathological features, and clinical outcomes of early MBC are different from that of FBC. Further studies on individualized treatment approaches in MBC are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.